Somatostatin Analogues Compared With Placebo and Other Pharmacologic Agents in the Management of Symptoms of Inoperable Malignant Bowel Obstruction: A Systematic Review

Tuca, 2012, Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution, Cancer Manag Res, 4, 159, 10.2147/CMAR.S29297

Ripamonti, 2005, Pathophysiology and management of malignant bowel obstruction, 496

Frank, 1997, Medical management of intestinal obstruction in terminal care, Can Fam Physician, 43, 259

Mercadante, 2009, Intestinal dysfunction and obstruction, 1267

Anthony, 2007, Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction, J Pain Symptom Manage, 34, S49, 10.1016/j.jpainsymman.2007.04.011

Ripamonti, 2003, Treatment and prognosis, 465

Currow, 2015, Double-Blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction, J Pain Symptom Manage, 49, 814, 10.1016/j.jpainsymman.2014.09.013

Peng, 2015, Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer, World J Surg Oncol, 13, 50, 10.1186/s12957-015-0455-3

Kubota, 2013, Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer, Asian Pac J Cancer Prev, 14, 7107, 10.7314/APJCP.2013.14.12.7107

Zhang, 2006, Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction, Dig Liver Dis, 38, 188, 10.1016/j.dld.2005.10.010

Khoo, 1994, Palliation of malignant intestinal obstruction using octreotide, Eur J Cancer, 30A, 28, 10.1016/S0959-8049(05)80012-7

DeBernardo, 2009, Surgical management of malignant bowel obstruction: strategies toward palliation of patients with advanced cancer, Curr Oncol Rep, 11, 287, 10.1007/s11912-009-0040-4

Mercadante, 2007, Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review, J Pain Symptom Manage, 33, 217, 10.1016/j.jpainsymman.2006.06.014

Ghoshal, 2016, Medical management of pediatric malignant bowel obstruction in a patient with Burkitt's lymphoma and ataxia telangiectasia using continuous ambulatory drug delivery system, J Pain Palliat Care Pharmacother, 30, 44, 10.3109/15360288.2015.1134748

Hardy, 1998, Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction, Palliat Med, 12, 437, 10.1191/026921698666334766

Laval, 2000, The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction?, Palliat Med, 14, 3, 10.1191/026921600669298725

Ripamonti, 2000, Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective, randomized trial, J Pain Symptom Manage, 19, 23, 10.1016/S0885-3924(99)00147-5

Mercadante, 2000, Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction, Support Care Cancer, 8, 188, 10.1007/s005200050283

Mittal, 2014, Nonopioid pharmacological management of malignant bowel obstruction: a New Zealand-wide survey, J Palliat Med, 17, 1249, 10.1089/jpm.2014.0176

NHS Scotland. Scottish palliative care guidelines: Bowel obstruction. Available at: http://www.palliativecareguidelines.scot.nhs.uk. Accessed March 25, 2015.

Fraserhealth: Hospice palliative care program symptom guidelines: Malignant bowel obstruction. Available at: https://www.fraserhealth.ca/media/13FHSymptomGuidelinesMalignantBowelObstruction.pdf. Accessed March 25, 2016.

Laval, 2014, Recommendations for bowel obstruction with peritoneal carcinomatosis, J Pain Symptom Manage, 48, 75, 10.1016/j.jpainsymman.2013.08.022

Ferguson, 2015, Management of intestinal obstruction in advanced malignancy, Ann Med Surg, 4, 264, 10.1016/j.amsu.2015.07.018

Soriano, 2011, Malignant bowel obstruction: individualized treatment near the end of life, Cleve Clin J Med, 78, 197, 10.3949/ccjm.78a.10052

Murphy, 2010, Octreotide, J Pain Symptom Manage, 40, 142, 10.1016/j.jpainsymman.2010.05.002

Allen, 2000, Design, synthesis and biological evaluation of 3-amino-3-phenylpropionamide derivatives as novel mu opioid receptor ligands, Bioorg Med Chem Lett, 10, 523, 10.1016/S0960-894X(00)00034-2

Ma, 2010, Octreotide for inoperable malignant bowel obstruction, Cochrane Database Syst Rev, 10.1002/14651858.CD008396

Mystakidou, 2002, Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial, Anticancer Res, 22, 1187

Ripamonti, 2001, Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer, Support Care Cancer, 9, 223, 10.1007/s005200000198

Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, e1000097, 10.1371/journal.pmed.1000097

Shamseer, 2015, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation, BMJ, 349, g7647, 10.1136/bmj.g7647

Higgins, 2008, Chapter 8: assessing risk of bias in included 11 studies

Laval, 2012, SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction, Bull Cancer, 99, E1, 10.1684/bdc.2011.1535

Mariani, 2012, Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study, J Clin Oncol, 30, 4337, 10.1200/JCO.2011.40.5712

Kunz, 1998, The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials, BMJ, 317, 1185, 10.1136/bmj.317.7167.1185

Saxby, 2007, How should we measure emesis in palliative care?, Palliat Med, 21, 369, 10.1177/0269216307080173

Bellavance, 2012, Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction, J Clin Oncol, 30, 4290, 10.1200/JCO.2012.45.0536

Chakraborty, 2011, Malignant bowel obstruction: natural history of a heterogeneous patient population followed prospectively over two years, J Pain Symptom Manage, 41, 412, 10.1016/j.jpainsymman.2010.05.007

Zelek, 2013, Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis, J Clin Oncol, 31, 2519, 10.1200/JCO.2012.48.4634

Mercadante, 2015, Octreotide for malignant bowel obstruction: commentary on Currow et al, J Pain Symptom Manage, 49, 813, 10.1016/j.jpainsymman.2015.04.001

Hwang, 2013, Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital, Support Care Cancer, 21, 2817, 10.1007/s00520-013-1860-1

Arvieux, 2005, Treatment of malignant intestinal obstruction. A prospective study over 80 cases [French], Ann de Chirurgie, 130, 470, 10.1016/j.anchir.2005.05.011

Barrelet, 1997, Role of octreotide in the management of malignant intestinal obstruction [French], Medecine Hyg, 55, 1337

Hisanaga, 2008, Efficacy of octreotide acetate for malignant gastrointestinal obstruction, Ann Oncol, 19, viii254

Kilonzo, 2014, A prospective evaluation of octreotide in the palliation of gastrointestinal symptoms, Palliat Med, 28, 596

Shima, 2008, Clinical efficacy and safety of octreotide (SMS201-995) in terminally Ill Japanese cancer patients with malignant bowel obstruction, Jpn J Clin Oncol, 38, 354, 10.1093/jjco/hyn035

Tanimura, 2010, Effective made of octreotide intravenous administration for malignant gastrointestinal obstruction in terminal cancer patients, Gan To Kagaku Ryoho, 37, 1991

Uchino, 2011, Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage, Gan To Kagaku Ryoho, 38, 255

Watari, 2012, A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer, Int J Gynecol Cancer, 22, 692, 10.1097/IGC.0b013e318244ce93

Mercadante, 1993, Octreotide in relieving gastrointestinal symptoms due to bowel obstruction, Palliat Med, 7, 295, 10.1177/026921639300700406

Mangili, 2005, Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis, Int J Gynecol Cancer, 15, 830, 10.1111/j.1525-1438.2005.00144.x

Mercadante, 1995, Bowel obstruction in home-care cancer patients: four years experience, Support Care Cancer, 3, 190, 10.1007/BF00368889

Mangili, 1996, Octreotide in the management of bowel obstruction in terminal ovarian cancer, Gynecol Oncol, 61, 345, 10.1006/gyno.1996.0154

Mercadante, 2004, Aggressive pharmacological treatment for reversing bowel obstruction, J Pain Symptom Manage, 28, 412, 10.1016/j.jpainsymman.2004.01.007

Porzio, 2011, Can malignant bowel obstruction in advanced cancer patients be treated at home?, Support Care Cancer, 19, 431, 10.1007/s00520-010-1009-4

Weber, 2009, Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics, Am J Hosp Palliat Care, 26, 84, 10.1177/1049909108327967

Matulonis, 2005, Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer, J Pain Symptom Manage, 30, 563, 10.1016/j.jpainsymman.2005.05.018

Massacesi, 2006, Sustained release octreotide may have a role in the treatment of malignant bowel obstruction, Palliat Med, 20, 715, 10.1191/0269216306070751

Krouse, 2007, The international conference on malignant bowel obstruction: a meeting of the minds to advance palliative care research, J Pain Symptom Manage, 34, S1, 10.1016/j.jpainsymman.2007.04.005

Shelby-James, 2012, Designing and conducting randomized controlled trials in palliative care: a summary of discussions from the 2010 clinical research forum of the Australian Palliative Care Clinical Studies Collaborative, Palliat Med, 26, 1042, 10.1177/0269216311417036

Laneader, 2007, Ethical issues in research to improve the management of malignant bowel obstruction: challenges and recommendations, J Pain Symptom Manage, 34, S20, 10.1016/j.jpainsymman.2007.04.007

LeBlanc, 2012, Considerations in reporting palliative care clinical trials: standardizing information reported and authorship practices, Curr Opin Support Palliat Care, 6, 494, 10.1097/SPC.0b013e3283597259

Keeley, 2004, Making the GRADE editorial, Palliat Med, 18, 675, 10.1191/0269216304pm974ed

Skrabanek, 1989, 30

Schulz, 2010, CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials, BMJ, 340, c332, 10.1136/bmj.c332

Bafeta, 2012, Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study, BMJ, 344, e813, 10.1136/bmj.e813

Weinberger, 2001, Multisite randomized controlled trials in health services research: scientific challenges and operational issues, Med Care, 39, 627, 10.1097/00005650-200106000-00010

Altman, 2001, The revised CONSORT statement for reporting randomized trials: explanation and elaboration, Ann Intern Med, 134, 663, 10.7326/0003-4819-134-8-200104170-00012

Chêne, 1998, Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group, Control Clin Trials, 19, 233, 10.1016/S0197-2456(97)00145-1

Hussain, 2016, Missing data in randomized controlled trials testing palliative interventions pose a significant risk of bias and loss of power: a systematic review and meta-analyses, J Clin Epidemiol, 74, 57, 10.1016/j.jclinepi.2015.12.003